Effects of the neurotensin NTS1 receptor agonist PD149163 on visual signal detection in rats

European Journal of Pharmacology

Volumn 721, Issue 1-3, 2013, Pages 201-207

  Hillhouse, Todd M ^a   Prus, Adam J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NORTHERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Antipsychotic; Attention; Neurotensin; NTS1 receptor; PD149163; Visual signal detection

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; N2 (2,6 DIAMINOHEXYL)LYSYLPROLYLTRYPTOPHYL 3 METHYLVALYLLEUCINE ETHYL ESTER; NEUROTENSIN RECEPTOR; NICOTINE; PD 14963; PLACEBO; RACLOPRIDE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DISTURBANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; EXPERIMENTAL RAT; MALE; NONHUMAN; OPERANT BEHAVIORAL TEST; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; RESPONSE TIME; SCHIZOPHRENIA; SIGNAL DETECTION; STIMULUS RESPONSE; TASK PERFORMANCE; VISUAL SYSTEM FUNCTION;

ANTIPSYCHOTIC; ATTENTION; NEUROTENSIN; NTS(1) RECEPTOR; PD149163; VISUAL SIGNAL DETECTION;

ANIMALS; ATTENTION; MALE; NEUROTENSIN; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, NEUROTENSIN; VISUAL PERCEPTION;

EID: 84890117875     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.09.035     Document Type: Article

References (57)

1. J. Arnt, and T. Skarsfeldt Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence Neuropsychopharmacology 18 1998 63 101 (Pubitemid 28026679)
2. N. Azmi, C. Norman, C.H. Spicer, and G.W. Bennett Effects of a neurotensin analogue (PD149163) and antagonist (SR142948A) on the scopolamine-induced deficits in a novel object discrimination task Behavioural Pharmacology 17 2006 357 362 (Pubitemid 44258984)
3. E.B. Binder, B. Kinkead, M.J. Owens, and C.B. Nemeroff Neurotensin and dopamine interactions Pharmacological Reviews 53 2001 453 486 (Pubitemid 33136236)
4. C. Bolden, B. Cusack, and E. Richelson Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells Journal of Pharmacology and Experimental Therapeutics 260 1992 576 580
5. M. Boules, L. Warrington, A. Fauq, D. McCormick, and E. Richelson A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity European Journal of Pharmacology 426 2001 73 76 (Pubitemid 32781790)
6. S. Briody, M. Boules, A. Oliveros, I. Fauq, and E. Richelson Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance Behavioural Brain Research 207 2010 118 124
7. P.J. Bushnell Detection of visual signals by rats: effects of signal intensity, event rate, and task type Behavioural Processes 46 1999 141 150 (Pubitemid 29257908)
8. P.J. Bushnell, W.M. Oshiro, and B.K. Padnos Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention Psychopharmacology 134 1997 230 241 (Pubitemid 27520977)
9. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, and N.C. Tye Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96 (Pubitemid 26053226)
10. F.P. Bymaster, C.C. Felder, E. Tzavara, G.G. Nomikos, D.O. Calligaro, and D.L. McKinzie Muscarinic mechanisms of antipsychotic atypicality Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 2003 1125 1143 (Pubitemid 37464958)
11. B. Cusack, M. Boules, B.M. Tyler, A. Fauq, D.J. McCormick, and E. Richelson Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol Brain Research 856 2000 48 54 (Pubitemid 30085510)
12. G.M. Dillon, D. Shelton, A.P. McKinney, M. Caniga, J.N. Marcus, and M.T. Ferguson Prefrontal cortex lesions and scopolamine impair attention performance of C57BL/6 mice in a novel 2-choice visual discrimination task Behavioural Brain Research 204 2009 67 76
13. D. Feifel, G. Melendez, R.J. Murray, D.N. Tina-Tran, M.A. Rullan, and P.D. Shilling The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance Psychopharmacology 200 2008 197 203
14. D. Feifel, G. Melendez, K. Priebe, and P.D. Shilling The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats Behavioural Brain Research 181 2007 278 286 (Pubitemid 46898666)
15. D. Feifel, G. Melendez, and P.D. Shilling Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects Neuropsychopharmacology 29 2004 731 738 (Pubitemid 38402480)
16. D. Feifel, S. Mexal, G. Melendez, P.Y. Liu, J.R. Goldenberg, and P.D. Shilling The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog Neuropsychopharmacology 34 2009 2011 2018
17. D. Feifel, T.L. Reza, D.J. Wustrow, and M.D. Davis Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist Journal of Pharmacology and Experimental Therapeutics 288 1999 710 713 (Pubitemid 29119685)
18. D. Feifel, P.D. Shilling, and G. Melendez Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats Behavioral Neuroscience 125 2011 268 272
19. S.B. Glickstein, D.A. Desteno, P.R. Hof, and C. Schmauss Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention Cerebral Cortex 15 2004 1016 1024
20. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153 1996 321 330 (Pubitemid 26074706)
21. M.F. Green, R.S. Kern, D.L. Braff, and J. Mintz Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophrenia Bulletin 26 2000 119 136 (Pubitemid 30317696)
22. S.K. Grimond-Billa, C. Norman, and G W.B. Cassaday, H.J. Selectively increased trace conditioning under the neurotensin agonist PD 149163 in an aversive procedure in which SR 142948A was without intrinsic effect Journal of Psychopharmacology 22 2008 290 299 (Pubitemid 351847441)
23. M.K. Hadden, K.S. Orwig, K.P. Kokko, J. Mazella, and T.A. Dix Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues Neuropharmacology 49 2005 1149 1159 (Pubitemid 41608639)
24. A.A. Harrison, B.J. Everitt, and T.W. Robbins Doubly dissociable effects of median- and dorsal-raphe lesions on the performance of the five-choice serial reaction time test of attention in rats Behavioural Brain Research 89 1-2 1997 135 149 (Pubitemid 28062706)
25. R.W. Heinrichs, and K.K. Zakzanis Neurocognitive deficit in schizophrenia: a quantitative review of the evidence Neuropsychology 12 1998 426 445 (Pubitemid 28323862)
26. P. Hertel, C.K. Olsen, and J. Arnt Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour European Journal of Pharmacology 439 2002 107 111 (Pubitemid 34286613)
27. E.N. Holly, B. Ebrecht, and A.J. Prus The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats European Neuropsychopharmacology 21 2011 526 531
28. S. Kähkönen, J. Ahveninen, I.P. Jääskeläinen, S. Kaakkola, R. Näätänen, and J. Huttunen Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study Neuropsychopharmacology 25 2001 498 504 (Pubitemid 32830954)
29. Y. Kaneda, K. Jayathilak, and H. Meltzer Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment Psychiatry Research 178 2010 57 62
30. J.T. Kantrowitz, and L. Citrome Lurasidone for schizophrenia: what's different? Expert Review of Neurotherapeutics 12 2012 265 273
31. R.S. Keefe, and W.S. Fenton How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bulletin 33 2007 912 920 (Pubitemid 47216649)
32. B.M. Kelley, and J.H. Porter The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats Pharmacology Biochemistry and Behavior 57 1997 707 719 (Pubitemid 27334446)
33. R. Kondrad, and J. Burk Transient disruption of attentional performance following escalating amphetamine administration in rats Psychopharmacology 175 2004 436 442 (Pubitemid 39362041)
34. J.A. McQuail, and J.A. Burk Evaluation of muscarinic and nicotinic receptor antagonists on attention and working memory Pharmacology Biochemistry and Behavior 85 2006 796 803 (Pubitemid 46149009)
35. V. Martinez, and M. Sarter Detection of the moderately beneficial cognitive effects of low-dose treatment with haloperidol or clozapine in an animal model of the attentional impairments of schizophrenia Neuropsychopharmacology 33 2008 2635 2647
36. H.Y. Meltzer What's atypical about atypical antipsychotic drugs? Current Opinion in Pharmacology 4 2004 53 57 (Pubitemid 38145838)
37. H.Y. Meltzer Update on typical and atypical antipsychotic drugs Annual Review of Medicine 64 2013 393 406
38. K. Mishima, M. Fujii, N. Aoo, T. Yoshikawa, Y. Fukue, and Y. Honda The pharmacological characterization of attentional processes using a two-lever choice reaction time task in rats Biological and Pharmaceutical Bulletin 25 2002 1570 1576 (Pubitemid 39663672)
39. C.B. Nemeroff Neurotensin: perchance an endogenous neuroleptic? Biological Psychiatry 15 1980 283 302 (Pubitemid 10130688)
40. K.A. Petri, M. Bubser, C.D. Casey, M.D. Davis, B.L. Roth, and A.Y. Deutch The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat Neuropsychopharmacology 29 2004 1878 1888 (Pubitemid 39336799)
41. 3 receptors: molecular dynamics refinement and docking evaluation PLoS ONE 7 2012 e44316
42. A.J. Prus, L.E. Baker, and H.Y. Meltzer Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms Pharmacology Biochemistry and Behavior 77 2004 199 208 (Pubitemid 38125151)
43. A.J. Prus, S.D. Philibin, A.L. Pehrson, C.L. Stephens, R.N. Cooper, and L.E. Wise Generalization testing with atypical and typical antipsychotic drugs in rats trained to discriminate 5.0 mg/kg clozapine from vehicle in a two-choice drug discrimination task Drug Development Research 64 2005 55 65 (Pubitemid 40605003)
44. A.H. Rezvani, P.J. Bushnell, and E.D. Levin Effects of nicotine and mecamylamine on choice accuracy in an operant visual signal detection task in female rats Psychopharmacology 16 2002 369 375 (Pubitemid 35435712)
45. A.H. Rezvani, D.P. Caldwell, and E.D. Levin Nicotinic-serotonergic drug interactions and attentional performance in rats Psychopharmacology 179 2005 521 528 (Pubitemid 40674752)
46. A.H. Rezvani, and E.D. Levin Nicotine-antipsychotic drug interactions and attentional performance in female rats European Journal of Pharmacology 486 2004 175 182 (Pubitemid 38224528)
47. A.H. Rezvani, E. Kholdebarin, E. Dawson, and E.D. Levin Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats International Journal of Neuropsychopharmacology 11 2008 63 70
48. B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma, Y. Shen, H.Y. Meltzer, and D.R. Sibley Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors Journal of Pharmacology and Experimental Therapeutics 268 1994 1403 1410 (Pubitemid 24100360)
49. A. Schotte, P.F. Janssen, W. Gommeren, W.H. Luyten, P. Van Gompel, and A.S. Lesage Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacology 124 1996 57 73 (Pubitemid 26112775)
50. P.D. Shilling, E. Richelson, and D. Feifel The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition Behavioural Brain Research 143 2003 7 14 (Pubitemid 36802179)
51. M. Shoaib, and L. Bizarro Deficits in a sustained attention task following nicotine withdrawal in rats Psychopharmacology 178 2005 211 222 (Pubitemid 40379216)
52. F. St-Galais, C. Jomphe, and L.E. Trudeau The role of neurotensin in central nervous system pathophysiology: What is the evidence? Journal of Psychiatry and Neuroscience 31 2006 229 245 (Pubitemid 44085829)
53. P.G. Strange Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects Pharmacological Reviews 53 2001 119 133 (Pubitemid 32173111)
54. T.R. Werkman, C.G. Kruse, H. Nievelstein, S.K. Long, and W.J. Wadman Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area Neuroscience 95 2000 417 423
55. N.D. Woodward, S.E. Purdon, H.Y. Meltzer, and D.H. Zald A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia International Journal of Neuropsychopharmacology 8 2005 457 472 (Pubitemid 41002500)
56. N.D. Woodward, S.E. Purdon, H.Y. Meltzer, and D.H. Zald A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects Schizophr Research 89 2006 211 224
57. D.J. Wustrow, M.D. Davis, H.C. Akunne, A.E. Corbin, J.N. Wiley, L.D. Wise, and T.G. Heffner Reduced amide bond neurotensin 8-13 mimetics with potent in vivo activity Bioorganic and Medicinal Chemistry Letters 5 1995 997 1002